Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

BACKGROUND: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, and high-risk early breast cancer (EBC), with indications varying by...

Descripción completa

Detalles Bibliográficos
Autores principales: Paluch-Shimon, Shani, Neven, Patrick, Huober, Jens, Cicin, Irfan, Goetz, Matthew P., Shimizu, Chikako, Huang, Chiun-Sheng, Lueck, Hans Joachim, Beith, Jane, Tokunaga, Eriko, Contreras, Jessica Reyes, de Sant’Ana, Rosane Oliveira, Wei, Ran, Shahir, Ashwin, Nabinger, Sarah C., Forrester, Tammy, Johnston, Stephen R. D., Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900651/
https://www.ncbi.nlm.nih.gov/pubmed/36756142
http://dx.doi.org/10.1177/17588359231151840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900651/
https://www.ncbi.nlm.nih.gov/pubmed/36756142
http://dx.doi.org/10.1177/17588359231151840

Ejemplares similares